Virlaza™ Improves Lung Function, Mechanics and Inflammation and Muscle Strength of Post-Covid-19 Patient: A Case Report

Author(s): Maysa Alves Rodrigues Brandao-Rangel, Dobroslav Melamed, Claudio Ricardo Frison, Razi Ronen, Boris Brill, Rodolfo P Vieira

Coronavirus disease 2019 (COVID-19) affects different organs and a severe pro-inflammatory response, denominated “cytokine storm” have been described as a key underlying mechanism. The lungs are the most affected organ, and a fibrotic response after infection by COVID-19 is often found. This case report demonstrates that 12 days of oral administration of Virlaza™, an herbal medicine developed in Israel (based on tinctures and natural antioxidants), was able to accelerate the lung recovery of a moderate/severe post-COVID-19 patient, who presents metabolic syndrome, characterized by grade II obesity, dyslipidemia, and hypertension.

After 12 days of hospitalization needing high flow nasal oxygen, non-invasive ventilation, awake (non-intubated) proning, the patient was discharged still presenting the following characteristics: 75% of ground-glass opacities of the lungs in computerized tomography (CT), severe reduction of the lung function, high levels of fractional exhaled nitric oxide (FeNO), leukopenia and neutrophilia, reduced respiratory muscle strength and peripheral muscle strength. So, a very quick recovery was observed after 12 days of Virlaza™, resulting in an improvement to 25% ground-glass opacities of the lungs in the CT, as well as an improvement for all parameters of lung function, FeNO, normalization of blood leukocytes and improvement of respiratory and peripheral muscle strength. So, Virlaza™ may be considered as an herbal medicine able to improve the recovery of post-COVID-19 patients and reduce COVID-19 comorbidities.